Incidence of gastric cancer ‐ modified ITT analysis Histological examination · healthy asymptomatic H. pylori‐infected individuals
H. pylori eradication therapy probably leads to lower incidence of gastric cancer ‐ modified ITT analysisHistological… compared with control (moderate certainty).
1 finding from 1 review
Death from gastric cancer ‐ modified ITT analysis · healthy asymptomatic H. pylori‐infected individuals
H. pylori eradication therapy probably leads to lower death from gastric cancer ‐ modified ITT analysis compared with control (moderate certainty).
1 finding from 1 review
Death Analysis 1.1 · healthy asymptomatic H. pylori‐infected individuals
H. pylori eradication therapy showed no clear difference in death from all causes ‐ modified ITT analysis compared with control (moderate certainty).
1 finding from 1 review
Incidence of oesophageal squamous cell carcinoma ‐ modified ITT analysis · healthy asymptomatic H. pylori‐infected individuals
H. pylori eradication therapy showed no clear difference in incidence of oesophageal squamous cell carcinoma ‐ modified ITT… compared with control (moderate certainty).
1 finding from 1 review
Adverse events · healthy asymptomatic H. pylori‐infected individuals
1 finding from 1 review
Remission · induction of remission in Crohn's disease
It is very uncertain whether probiotics changes induction of remission compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · induction of remission in Crohn's disease
It is very uncertain whether probiotics changes adverse events leading to withdrawal compared with placebo (very low certainty).
1 finding from 1 review
Disimpaction · management of impacted food bolus in the oesophagus
Diazepam and glucagon showed no clear difference in disimpaction compared with placebo (low certainty).
1 finding from 1 review
Clinical relapse · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes clinical relapse (12 to 52 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (52 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
Clinical relapse · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes clinical relapse (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
1 finding from 1 review
Maintenance of clinical remission · Patients with quiescent ulcerative colitis
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) showed no clear difference in maintenance of clinical remission (24 to 52 weeks) compared with 5‐ASA (mesalazine) (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes withdrawal due to adverse events (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
1 finding from 1 review
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maintenance of clinical remission · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes maintenance of clinical remission (52 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (48 to 52 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review